EVIPNet Brasil > Pesquisa > id:"lil-774625"
adicionar à sua lista
1.

Comparative study between two recombinant human NPH insulin formulations for the treatment of type 2 diabetes mellitus

Autor(es): Rassi, Nelson; Moraes, Sandra Maria Campos Teixeira de; Alves, Adriana Ganam; Cavalheiro, Daniela Cunha; Moreira, Josianny Mesquita; Bellório, Karini Bruno; Abreu, Fernanda Cruvinel de; Prata, Paulo Roberto Mendonça; Teixeira, Leonardo de Souza; Rassi, Salvador
Fonte: Arch. endocrinol. metab. (Online);60(1): 47-53, Feb. 2016. tab
[ ID: 774625 ] Idioma: Inglês
Tipo de publicação: Estudo Comparativo; Ensaio Clínico Controlado Aleatório; Research Support, Non-U.S. Gov't
ABSTRACT Objective To compare the effects of the neutral protamine Hagedorn (NPH) recombinant human insulin formulations Gansulin and Humulin N® on the glycemic control of patients with type 2 diabetes mellitus (T2DM). Subjects and methods Prospective, double-blind, randomized, parallel, single-center study of 37 individuals with T2DM treated with NPH insulin formulations. The Tukey-Kramer test for multiple comparisons, the Wilcoxon paired comparison test and the Chi-Square test were used for the statistical analyses. The significance level was set at 5% (p < 0.05). Results The NPH insulin formulations Humulin and Gansulin similarly reduced the HbA1c levels observed at the end of the study compared with the values obtained at the beginning of the study. In the Humulin group, the initial HbA1c value of 7.91% was reduced to 6.56% (p < 0.001), whereas in the Gansulin group, the reduction was from 8.18% to 6.65% (p < 0.001). At the end of the study, there was no significant difference between the levels of glycated hemoglobin (p = 0.2410), fasting plasma glucose (FG; p = 0.9257) and bedtime plasma glucose (BG; p = 0.3906) between the two insulin formulations. There was no nt difference in the number of hypoglycemic events between the two insulin formulations, and no severe hyp episodes were recorded. Conclusion This study demonstrated similar glycemic control by NPH insulin Gansulin compared with human insulin Humulin N® in patients with T2DM.